Zimbabwe has declined a significant American healthcare agreement valued at $367m (272 million pounds) over five years over Washington's insistence on confidential data.
This rejection came to light following a government memo dated December was disclosed, revealing that President Emmerson Mnangagwa believed the arrangement was "unbalanced".
A government representative later explained that the US was requesting genetic material for scientific study and commercial gain but refused to guarantee the resulting advantages from future vaccines.
"We must now begin the challenging and unfortunate task of winding down our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had provided more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has appealed for more dialogue to reach a agreement agreeable to both sides so the country's critical HIV treatment initiative can be sustained.
Broader Context
This development follows a similar situation in Kenya, where a high court suspended a similar health funding agreement after concerns were raised about the safety of citizens' health data.
Since returning to office last year, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the US government, but Trump argued its expenditure was "wasteful" and his administration was pursuing direct bilateral agreements to boost transparency and responsibility.
According to statements, 16 African countries have so far signed these new agreements, representing over $18.3bn of fresh investment.
Specifics of the Rejected Agreement
This assistance for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this partnership would have delivered significant advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently on antiretroviral therapy via American-funded initiatives," Tremont said.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"Zimbabwe was being asked to provide its genetic material and health information for a long time, with no corresponding promise of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that might be developed from that provided information," Mangwana explained.
"Put simply, our nation would provide the raw materials for medical research without any assurance that the final treatments would be accessible to our population if a new health crisis emerge."
Sovereignty and Global Health
Mangwana further noted that the American exit from the global health body and its pursuit of bilateral health agreements were upending structures already established through the global health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme created to manage potential global health emergencies.
"This mechanism is intended to ensure that when a nation contributes its data, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised solely by those with the capability to develop them."
These objections regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We welcome continued discussions with our US partners on how subsequent co-operation could be designed in a way that respects the sovereignty and dignity of both nations."
Health Experts Reaction
Medical experts stated it acknowledged the official position, but urged that negotiations need to persist considering much of the nation's Aids initiatives depended on external financing.
"Where technical issues exist, such as those involving information security or implementation frameworks, these can frequently be resolved through technical clarification and mutually agreed protections," the group commented.
This impasse highlights the continuing debate between receiving vital international aid and safeguarding local interests in an increasingly interconnected world.